• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Technology & Startups

Weight-loss company Noom pivots to smaller doses of compounded Wegovy

May 20, 2025
in Technology & Startups
Reading Time: 4 mins read
A A
0
3
SHARES
7
VIEWS
Share on FacebookShare on Twitter


By Amina Niasse

NEW YORK (Reuters) -Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk’s Wegovy as the U.S. drugs regulator clamps down on mass production of copies of the in-demand medicine.

Noom will offer its version of compounded semaglutide – the active ingredient in Wegovy and diabetes drug Ozempic – as part of a program personalized for patients, which it says will comply with changing U.S. Food and Drug Administration regulations.

Demand for the new generation of highly effective but pricey weight-loss drugs has catapulted sales at Noom and rival telehealth sites including Hims & Hers, WeightWatchers and Ro over the past two years.

Taking small doses of the weight-loss drugs, sometimes referred to as micro-dosing, has become popular due to the high cost and side effects of the medicines.

For hundreds of dollars less than the name brand drugs, patients could access doctors and pharmacy-made versions based on semaglutide or tirzepatide, the main ingredient in Eli Lilly’s rival Zepbound and Mounjaro, due to a regulatory exception allowing them during drug shortages.

However, the FDA declared the shortages over and its sunset deadline for compounded versions of Wegovy is May 22.

Noom offers its compounded semaglutide at a starting price of $149 for the first month. A 2.5 milligram vial of Wegovy or Zepbound costs $349, according to Novo and Lilly websites.

Analysts have said the telehealth companies must pivot to working with branded drugs in order to survive after WeightWatchers filed for bankruptcy.

Jeffrey Egler, Noom’s chief medical officer, said providers would determine if patients need a smaller dose because of concerns about gastrointestinal side effects, or to boost adherence or help keep lost weight off, for example.

Noom CEO Geoff Cook said the move would not conflict with regulations. “There is a personalized, and there has always been a personalized, exception,” Cook said.

Novo Nordisk said it is illegal to make or sell semaglutide copies in the U.S. with only rare exceptions.

“As the FDA has warned, compounders cannot evade federal compounding laws by selling knockoff semaglutide drugs with manipulated, unnecessary, and pretextual changes to doses and ingredients,” a Novo Nordisk spokesperson said in a statement.

DOSING

Noom’s documents show that a personalized approach could start with half the typical starter 0.25-milligram dose of Wegovy and gradually increase to about half the FDA-approved maximum dose of 2.4 mg over 20 weeks.

Noom said the move is not meant to capitalize on the microdosing trend, saying patients could increase their dose to the target, just more slowly.

Noom said it will continue selling branded Novo Nordisk drugs as well as Lilly’s Zepbound.

Clinical trials of Wegovy and Zepbound have shown the drugs can lead to reductions of 15% to 20% of a person’s body weight.

A recent study suggests that half the usual dose of semaglutide may be as effective a weight-loss tool as current dosing.

While compounders can create copies for individuals of doses not available in branded drugs, ongoing FDA reviews of whether tirzepatide and semaglutide fall into a category of drugs too complex to qualify for any compounding could put an end to the practice, said Rosalie Hoyle, a research scientist at Avalere.

“As it stands today, compounders still can technically make a personalized dose of semaglutide and tirzepatide,” she said.

(Reporting by Amina Niasse; Editing by Caroline Humer and Bill Berkrot)

Tags: branded drugsNoomNovo NordiskPersonalizedWegovyWeight loss drugs
Previous Post

Moncton Wildcats top Rimouski Océanic 3-2 to win first QMJHL title since 2010 – New Brunswick

Next Post

U.S. Says It Wants Trade, Not Aid, in Africa. Cuts Threaten Both.

Related Posts

Breaking down the true cost of AI data centers’ rapid growth across America

July 6, 2025
4

Read the exclusive pitch deck AI infrastructure startup Cerebrium used to nab $8.5 million from Gradient Ventures

July 6, 2025
5
Next Post

U.S. Says It Wants Trade, Not Aid, in Africa. Cuts Threaten Both.

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Police ID man who died after Corso Italia fight

December 23, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
Joe Rogan offers blunt 2-word solution to fix America

Joe Rogan offers blunt 2-word solution to fix America todayheadline

July 6, 2025

LeMaitre Vascular's SWOT analysis: niche market leader faces growth challenges todayheadline

July 6, 2025

Create Visuals, Content, and Presentations That Land with This $25 Bundle todayheadline

July 6, 2025
ET logo

Senior US official meets Dalai Lama in Dharamshala: Embassy todayheadline

July 6, 2025

Recent News

Joe Rogan offers blunt 2-word solution to fix America

Joe Rogan offers blunt 2-word solution to fix America todayheadline

July 6, 2025
7

LeMaitre Vascular's SWOT analysis: niche market leader faces growth challenges todayheadline

July 6, 2025
6

Create Visuals, Content, and Presentations That Land with This $25 Bundle todayheadline

July 6, 2025
4
ET logo

Senior US official meets Dalai Lama in Dharamshala: Embassy todayheadline

July 6, 2025
5

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Joe Rogan offers blunt 2-word solution to fix America

Joe Rogan offers blunt 2-word solution to fix America todayheadline

July 6, 2025

LeMaitre Vascular's SWOT analysis: niche market leader faces growth challenges todayheadline

July 6, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co